Drugs / Janagliflozin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03851432 | Jun 2019 → Apr 2020 | type 2 diabetes mellitus | Sihuan Pharmaceutical Holdings Group Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03811548 | May 2019 → Jun 2020 | type 2 diabetes mellitus | Sihuan Pharmaceutical Holdings Group Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Janagliflozin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03851432 ↗ |
| Route | Oral | “Study drug will be taken orally once daily.” NCT03811548 ↗ |